Interim Report Q2 2026
Apotea AB (publ) interim report Q2 2026: Continued strong profitability and stable growth
Net revenue for the second quarter increased by 10.9% (9.9) to SEK 2,025.9 million (1,826.2) and adjusted operating profit (EBIT) amounted to SEK 104.7 million (99.3), corresponding to an adjusted EBIT margin of 5.2% (5.4).
Second quarter (April 1 – June 30, 2026)
- Net revenue increased by 10.9% (9.9) to SEK 2,025.9 million (1,826.2)
- Gross margin was 27.5% (28.0)
- Operating profit (EBIT) amounted to SEK 104.4 million (93.1), corresponding to an EBIT margin of 5.2% (5.1)
- Adjusted operating profit (EBIT) amounted to SEK 104.7 million (99.3), corresponding to an adjusted EBIT margin of 5.2% (5.4)
- Adjusted operating profit (EBIT) excludes costs of SEK 0.3 million related to share-based payments. Items affecting comparability in the comparative period amounted to SEK -6.2 million
- Profit for the period amounted to SEK 81.1 million (71.7)
- Earnings per share before and after dilution was 0.78 SEK (0.69)
- Cash flow from operating activities was SEK 76.8 million (165.3)
January – June 2026
- Net revenue increased by 10.7% (12.5) to SEK 3,963.1 million (3,579.7)
- Gross margin was 27.9% (27.8)
- Operating profit (EBIT) amounted to SEK 205.7 million (185.5), corresponding to an EBIT margin of 5.2% (5.2)
- Adjusted operating profit (EBIT) amounted to SEK 206.0 million (191.7), corresponding to an adjusted EBIT margin of 5.2% (5.4)
- Adjusted operating profit (EBIT) excludes costs of SEK 0.3 million related to share-based payments. Items affecting comparability in the comparative period amounted to SEK -6.2 million
- Profit for the period amounted to SEK 159.5 million (143.5)
- Earnings per share before and after dilution was 1.54 SEK (1.38)
- Cash flow from operating activities was SEK 189.3 million (288.6)
Pär Svärdson, CEO, comments:
We delivered strong profitability and stable growth during the second quarter. At the same time, our efforts to accelerate growth continued unabated. This is a long-term effort, and while we are making good progress, it will take time before these initiatives are fully reflected in our growth trajectory. During the quarter, we started to scale up sales of our beauty and health offering in Norway through apotea.no. We also saw strong growth in our own brands, which now generate annual sales of more than SEK 100 million.
The result for the period January – June 2026 will be presented today at 09:30 (CEST) by Apotea’s CEO Pär Svärdson, COO & deputy CEO Sarah Ahnström and CFO Johan Mårild via a live webcast. The presentation will be held in English. To join the webcast please use the following link: https://apotea.events.inderes.com/q2-report-2026. If you wish to participate via telephone conference please use the following link: https://events.inderes.com/apotea/q2-report-2026/dial-in.